Diagnostics group Eurofins gets U.S. 'EUA' approval for home-based COVID-19 Test

Laboratory testing and diagnostics company Eurofins said its new at-home COVID nasal testing product had received 'Emergency Use Approval' (EUA) status from the U.S. Food & Drug Administration regulatory body.

PARIS, Oct 19 (Reuters) - Laboratory testing and diagnostics company Eurofins EUFI.PA said its new at-home COVID nasal testing product had received 'Emergency Use Approval' (EUA) status from the U.S. Food & Drug Administration regulatory body.

Eurofins said the EUA authorised self-collection kit gives consumers a convenient and quick option to test from the comfort of their home, with results reviewed by a licensed physician and provided via email within 24 hours of sample receipt.

Worldwide coronavirus cases crossed 40 million on Monday, according to a Reuters tally, as the onset of winter in the northern hemisphere fuelled a resurgence in the spread of the disease.

(Reporting by Sudip Kar-Gupta; Editing by Muralikumar Anantharaman)

((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More